324 related articles for article (PubMed ID: 36543113)
1. Spatial heterogeneity of infiltrating T cells in high-grade serous ovarian cancer revealed by multi-omics analysis.
Yang B; Li X; Zhang W; Fan J; Zhou Y; Li W; Yin J; Yang X; Guo E; Li X; Fu Y; Liu S; Hu D; Qin X; Dou Y; Xiao R; Lu F; Wang Z; Qin T; Wang W; Zhang Q; Li S; Ma D; Mills GB; Chen G; Sun C
Cell Rep Med; 2022 Dec; 3(12):100856. PubMed ID: 36543113
[TBL] [Abstract][Full Text] [Related]
2. Increased expression of IDO1 is associated with improved survival and increased number of TILs in patients with high-grade serous ovarian cancer.
Hoffmann I; Dragomir MP; Monjé N; Keunecke C; Kunze CA; Schallenberg S; Marchenko S; Schmitt WD; Kulbe H; Sehouli J; Braicu IE; Jank P; Denkert C; Darb-Esfahani S; Horst D; Sinn BV; Sers C; Bischoff P; Taube ET
Neoplasia; 2023 Oct; 44():100934. PubMed ID: 37703626
[TBL] [Abstract][Full Text] [Related]
3. T-Cell Receptor Repertoire Characteristics Associated with Prognostic Significance in High-Grade Serous Ovarian Carcinoma.
Kim JW; Kim S; Yang SY; Joung JG; Hwang S
Genes (Basel); 2023 Mar; 14(4):. PubMed ID: 37107543
[TBL] [Abstract][Full Text] [Related]
4. Spatial cytotoxic and memory T cells in tumor predict superior survival outcomes in patients with high-grade serous ovarian cancer.
Zhang G; Xu Q; Zhang X; Yang M; Wang Y; He M; Lu J; Liu H
Cancer Med; 2021 Jun; 10(12):3905-3918. PubMed ID: 33955198
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of tumor PD-L1 expression combined with CD8
Wang Q; Lou W; Di W; Wu X
Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
[TBL] [Abstract][Full Text] [Related]
6. Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer.
Pinto MP; Balmaceda C; Bravo ML; Kato S; Villarroel A; Owen GI; Roa JC; Cuello MA; Ibañez C
Gynecol Oncol; 2018 Oct; 151(1):10-17. PubMed ID: 30078505
[TBL] [Abstract][Full Text] [Related]
7. Identification of antigenic epitopes recognized by tumor infiltrating lymphocytes in high grade serous ovarian cancer by multi-omics profiling of the auto-antigen repertoire.
Millar DG; Yang SYC; Sayad A; Zhao Q; Nguyen LT; Warner K; Sangster AG; Nakatsugawa M; Murata K; Wang BX; Shaw P; Clarke B; Bernardini MQ; Pugh T; Thibault P; Hirano N; Perreault C; Ohashi PS
Cancer Immunol Immunother; 2023 Jul; 72(7):2375-2392. PubMed ID: 36943460
[TBL] [Abstract][Full Text] [Related]
8. Single-Cell RNA Sequencing Reveals the Tissue Architecture in Human High-Grade Serous Ovarian Cancer.
Xu J; Fang Y; Chen K; Li S; Tang S; Ren Y; Cen Y; Fei W; Zhang B; Shen Y; Lu W
Clin Cancer Res; 2022 Aug; 28(16):3590-3602. PubMed ID: 35675036
[TBL] [Abstract][Full Text] [Related]
9. Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer.
Stanske M; Wienert S; Castillo-Tong DC; Kreuzinger C; Vergote I; Lambrechts S; Gabra H; Gourley C; Ganapathi RN; Kolaschinski I; Budczies J; Sehouli J; Ruscito I; Denkert C; Kulbe H; Schmitt W; Jöhrens K; Braicu I; Darb-Esfahani S
Neoplasia; 2018 Mar; 20(3):280-288. PubMed ID: 29466768
[TBL] [Abstract][Full Text] [Related]
10. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer.
Webb JR; Milne K; Watson P; Deleeuw RJ; Nelson BH
Clin Cancer Res; 2014 Jan; 20(2):434-44. PubMed ID: 24190978
[TBL] [Abstract][Full Text] [Related]
11. Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts.
Woolaver RA; Wang X; Krinsky AL; Waschke BC; Chen SMY; Popolizio V; Nicklawsky AG; Gao D; Chen Z; Jimeno A; Wang XJ; Wang JH
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414263
[TBL] [Abstract][Full Text] [Related]
12. MMDAE-HGSOC: A novel method for high-grade serous ovarian cancer molecular subtypes classification based on multi-modal deep autoencoder.
Wang HQ; Li HL; Han JL; Feng ZP; Deng HX; Han X
Comput Biol Chem; 2023 Aug; 105():107906. PubMed ID: 37336028
[TBL] [Abstract][Full Text] [Related]
13. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
[TBL] [Abstract][Full Text] [Related]
14. Single-cell sequencing reveals effects of chemotherapy on the immune landscape and TCR/BCR clonal expansion in a relapsed ovarian cancer patient.
Ren Y; Li R; Feng H; Xie J; Gao L; Chu S; Li Y; Meng F; Ning Y
Front Immunol; 2022; 13():985187. PubMed ID: 36248860
[TBL] [Abstract][Full Text] [Related]
15. High expression of CD8 in the tumor microenvironment is associated with PD-1 expression and patient survival in high-grade serous ovarian cancer.
Ölmez F; Oğlak SC; Ölmez ÖF; Akbayır Ö; Yılmaz E; Akgöl S; Konal M; Seyhan NA; Kinter AK
Turk J Obstet Gynecol; 2022 Sep; 19(3):246-256. PubMed ID: 36149309
[TBL] [Abstract][Full Text] [Related]
16. Deciphering tumor immune microenvironment differences between high-grade serous and endometrioid ovarian cancer to investigate their potential in indicating immunotherapy response.
Yang H; Gu X; Fan R; Zhu Q; Zhong S; Wan X; Chen Q; Zhu L; Feng F
J Ovarian Res; 2023 Nov; 16(1):223. PubMed ID: 37993916
[TBL] [Abstract][Full Text] [Related]
17. Molecular cluster mining of high-grade serous ovarian cancer via multi-omics data analysis aids precise medicine.
Cai D; Liu T; Fang J; Liu Y
J Cancer Res Clin Oncol; 2023 Sep; 149(11):9151-9165. PubMed ID: 37178426
[TBL] [Abstract][Full Text] [Related]
18. Multi-omics study revealing the complexity and spatial heterogeneity of tumor-infiltrating lymphocytes in primary liver carcinoma.
Shi L; Zhang Y; Feng L; Wang L; Rong W; Wu F; Wu J; Zhang K; Cheng S
Oncotarget; 2017 May; 8(21):34844-34857. PubMed ID: 28422742
[TBL] [Abstract][Full Text] [Related]
19. Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer.
Zhang AW; McPherson A; Milne K; Kroeger DR; Hamilton PT; Miranda A; Funnell T; Little N; de Souza CPE; Laan S; LeDoux S; Cochrane DR; Lim JLP; Yang W; Roth A; Smith MA; Ho J; Tse K; Zeng T; Shlafman I; Mayo MR; Moore R; Failmezger H; Heindl A; Wang YK; Bashashati A; Grewal DS; Brown SD; Lai D; Wan ANC; Nielsen CB; Huebner C; Tessier-Cloutier B; Anglesio MS; Bouchard-Côté A; Yuan Y; Wasserman WW; Gilks CB; Karnezis AN; Aparicio S; McAlpine JN; Huntsman DG; Holt RA; Nelson BH; Shah SP
Cell; 2018 Jun; 173(7):1755-1769.e22. PubMed ID: 29754820
[TBL] [Abstract][Full Text] [Related]
20. Nomograms to Predict the Density of Tumor-Infiltrating Lymphocytes in Patients With High-Grade Serous Ovarian Cancer.
Dai D; Liu L; Huang H; Chen S; Chen B; Cao J; Luo X; Wang F; Luo R; Liu J
Front Oncol; 2021; 11():590414. PubMed ID: 33718143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
